Amarin (NASDAQ:AMRN), the pharma company that recently gained FDA approval for its hypertriglyceridemia drug Vascepa, will post its third-quarter earnings on Nov. 8. Although this therapeutic hasn't hit the market yet, it has the potential to grab market share from GlaxoSmithKline's (NYSE:GSK) drug Lovaza.

Since the drug was approved, investors have been waiting to hear about two important issues: whether Vascepa will be granted New Chemical Entity, or NCE, status by the FDA, and whether the company will be acquired. It is possible that Amarin will commercialize Vascepa on its own if it fails to be bought or find a strategic partner.

In the following video, health care analysts Max Macaluso and David Williamson discuss Amarin and what investors should be on the lookout for in its upcoming report.

Max Macaluso, Ph.D. holds no position in any company mentioned above. David Williamson owns shares of Amarin, but he holds no other position in any company mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.